Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70778 | 1.00 | TSHR (0.46) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL1133592 | 1.00 | — | — | |
| SCHEMBL5161881 | 0.91 | ALDH1A1 (0.47) | GAAALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL5434193 | 0.91 | HSD17B10 (0.47) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL14470272 | 0.91 | HSD17B10 (0.47) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL13569369 | 0.91 | HSD17B10 (0.47) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL2663549 | 0.91 | SIGMAR1 (0.45) | TSHRGAAALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL28738942 | 0.90 | — | — | |
| SCHEMBL65441 | 0.90 | ALDH1A1 (0.50) | TSHRGAAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL24016434 | 0.89 | KDM4E (0.50) | TSHRHSD17B10MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442949-B1 | CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2022-06-08 | — | — | EP | disclosed |
| WO-2017178301-A1 | CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2017-10-19 | — | — | WO | disclosed |
| US-9777022-B2 | Process for the preparation of macrocyclic polyazacarboxylate ligands and chelates | GUERBET (FR) | 2017-10-03 | — | — | US | disclosed |
| WO-2017098038-A1 | CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017098044-A1 | DIMERIC CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2017-06-15 | — | — | WO | disclosed |
| EP-2920156-B1 | PROCESS FOR THE PREPARATION OF MACROCYCLIC POLYAZACARBOXYLATE LIGANDS AND CHELATES | GUERBET SA (FR) | 2016-12-07 | — | — | EP | disclosed |
| US-20160185803-A1 | PROCESS FOR THE PREPARATION OF MACROCYCLIC POLYAZACARBOXYLATE LIGANDS AND CHELATES | MALLINCKRODT LLC | 2016-06-30 | — | — | US | disclosed |
| US-9315474-B2 | Process for the preparation of macrocyclic polyazacarboxylate ligands and chelates | LIEBEL-FLARSHEIM COMPANY LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150259304-A1 | PROCESS FOR THE PREPARATION OF MACROCYCLIC POLYAZACARBOXYLATE LIGANDS AND CHELATES | GUERBET (FR) | 2015-09-17 | — | — | US | disclosed |
| US-7989417-B2 | Linkers for radiopharmaceutical compounds | BRACCO IMAGING S.P.A. (IT) | 2011-08-02 | — | — | US | disclosed |
| US-7922998-B2 | bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy | BRACCO IMAGING S.P.A. (IT) | 2011-04-12 | — | — | US | disclosed |
| US-7611692-B2 | bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy | BRACCO IMAGING S.P.A. (IT) | 2009-11-03 | — | — | US | disclosed |
| US-7226577-B2 | Gastrin releasing peptide compounds | BRACCO IMAGING, S. P. A. (IT) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185803-A1 | PROCESS FOR THE PREPARATION OF MACROCYCLIC POLYAZACARBOXYLATE LIGANDS AND CHELATES | SSTR4, SSTR5, MVD | TSHR 422/4885HSD17B10 3901/4885MGAM 1521/4885 |
| US-20150259304-A1 | PROCESS FOR THE PREPARATION OF MACROCYCLIC POLYAZACARBOXYLATE LIGANDS AND CHELATES | SSTR4, SSTR5, MVD | TSHR 422/4885HSD17B10 3901/4885MGAM 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.